Dr Rachel Taylor
University College London Hospitals NHS Foundation Trust
A person’s fear of their sarcoma returning can have a huge impact on their quality of life. This project will explore the nature of fear of recurrence in patients with sarcoma, leading to the development of an intervention to help patients manage this difficult issue.
The project builds on previous work by the same research group, also funded by Sarcoma UK.
Development of a sarcoma specific intervention to manage fear of recurrence: REASSURE_ME
There is limited research on fear of recurrence (FoR) in patients with sarcoma, however it is an issue which can have a huge impact on a person’s psychological wellbeing. A previous study by this team collected data from over 1000 people with a previous sarcoma diagnosis and FoR was reported as a problem by the majority of these patients.
This study will explore the nature of FoR in sarcoma patients, with the aim of developing an intervention to manage it. This will be done by initially performing analysis of the group’s existing data looking for factors associated with FoR. A patient survey about FoR will also be administered in order to determine the prevalence and severity of identified factors. The results will then be compared to existing literature to determine if interventions developed for other cancer types are relevant for sarcoma.
Workshops will then be undertaken with healthcare professionals to determine how potential interventions could be supported in practice, and with patients in order to determine the barriers, facilitators and acceptability of the potential interventions.
Finally the group will identify a clinical trials unit with expertise in delivering non-drug trials, who will be co-applicants on a subsequent grant application. A workshop will be held with patients/healthcare professionals to define the best study design and outcome measures.
The key outcome from this study will be an intervention and national study designed to test this intervention, ready to submit for additional funding.